4/4
08:14 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its price target raised by analysts at HC Wainwright from $10.00 to $24.00. They now have a "buy" rating on the stock.
Medium
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its price target raised by analysts at HC Wainwright from $10.00 to $24.00. They now have a "buy" rating on the stock.
4/3
07:26 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Low
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
4/2
04:05 pm
cmpx
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Medium
Report
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
4/2
11:50 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $12.00 price target on the stock.
High
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $12.00 price target on the stock.
4/2
08:13 am
cmpx
Compass Therapeutics And 2 More Compelling Penny Stocks [Yahoo! Finance]
High
Report
Compass Therapeutics And 2 More Compelling Penny Stocks [Yahoo! Finance]
4/2
08:11 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock, up previously from $4.00.
High
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock, up previously from $4.00.
4/1
10:31 pm
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
High
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
4/1
08:00 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $32.00 price target on the stock.
Medium
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $32.00 price target on the stock.
4/1
07:00 am
cmpx
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Low
Report
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
3/31
04:05 pm
cmpx
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
High
Report
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
3/18
08:37 am
cmpx
With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest [Yahoo! Finance]
Low
Report
With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest [Yahoo! Finance]
3/2
10:33 am
cmpx
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 [Yahoo! Finance]
Medium
Report
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 [Yahoo! Finance]
2/27
08:00 am
cmpx
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Medium
Report
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
2/25
09:31 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $32.00 price target on the stock.
Medium
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $32.00 price target on the stock.
2/25
08:18 am
cmpx
Ottimo Pharma Strengthens Leadership Team with Senior Appointments [Yahoo! Finance]
Medium
Report
Ottimo Pharma Strengthens Leadership Team with Senior Appointments [Yahoo! Finance]
2/24
07:07 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $12.00 price target on the stock.
Low
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $12.00 price target on the stock.
2/19
04:17 pm
cmpx
Massachusetts-Based Biotech Soars On Analyst Coverage And Bullish Price Targer [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Massachusetts-Based Biotech Soars On Analyst Coverage And Bullish Price Targer [Globe and Mail, The (Toronto, Canada)]
2/19
07:06 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $12.00 price target on the stock.
Medium
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $12.00 price target on the stock.
2/10
05:05 pm
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its price target raised by analysts at Jefferies Financial Group Inc. from $7.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its price target raised by analysts at Jefferies Financial Group Inc. from $7.00 to $8.00. They now have a "buy" rating on the stock.
1/29
08:00 am
cmpx
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Medium
Report
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
1/8
11:29 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
1/8
09:46 am
cmpx
Compass Therapeutics announces advancement of a new drug candidate [Seeking Alpha]
High
Report
Compass Therapeutics announces advancement of a new drug candidate [Seeking Alpha]
1/8
09:21 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $32.00 price target on the stock.
High
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $32.00 price target on the stock.
1/8
08:00 am
cmpx
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
High
Report
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate